Literature DB >> 21310958

MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy.

Jianyin Long1, Yin Wang, Wenjian Wang, Benny H J Chang, Farhad R Danesh.   

Abstract

Although several recent publications have suggested that microRNAs contribute to the pathogenesis of diabetic nephropathy, the role of miRNAs in vivo still remains poorly understood. Using an integrated in vitro and in vivo comparative miRNA expression array, we identified miR-29c as a signature miRNA in the diabetic environment. We validated our profiling array data by examining miR-29c expression in the kidney glomeruli obtained from db/db mice in vivo and in kidney microvascular endothelial cells and podocytes treated with high glucose in vitro. Functionally, we found that miR-29c induces cell apoptosis and increases extracellular matrix protein accumulation. Indeed, forced expression of miR-29c strongly induced podocyte apoptosis. Conversely, knockdown of miR-29c prevented high glucose-induced cell apoptosis. We also identified Sprouty homolog 1 (Spry1) as a direct target of miR-29c with a nearly perfect complementarity between miR-29c and the 3'-untranslated region (UTR) of mouse Spry1. Expression of miR-29c decreased the luciferase activity of Spry1 when co-transfected with the mouse Spry1 3'-UTR reporter construct. Overexpression of miR-29c decreased the levels of Spry1 protein and promoted activation of Rho kinase. Importantly, knockdown of miR-29c by a specific antisense oligonucleotide significantly reduced albuminuria and kidney mesangial matrix accumulation in the db/db mice model in vivo. These findings identify miR-29c as a novel target in diabetic nephropathy and provide new insights into the role of miR-29c in a previously unrecognized signaling cascade involving Spry1 and Rho kinase activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310958      PMCID: PMC3064234          DOI: 10.1074/jbc.M110.194969

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.

Authors:  Seong-Yeon Park; Jung Hyun Lee; Minju Ha; Jin-Wu Nam; V Narry Kim
Journal:  Nat Struct Mol Biol       Date:  2008-12-14       Impact factor: 15.369

2.  Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation.

Authors:  Zhaoyong Li; Mohammad Q Hassan; Mohammed Jafferji; Rami I Aqeilan; Ramiro Garzon; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2009-04-02       Impact factor: 5.157

3.  Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells.

Authors:  Michael D Horwich; Phillip D Zamore
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

4.  A system for Cre-regulated RNA interference in vivo.

Authors:  Patrick Stern; Sophie Astrof; Stefan J Erkeland; Joshua Schustak; Phillip A Sharp; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

5.  Searching for miR-acles in cardiac fibrosis.

Authors:  Eva van Rooij; Eric N Olson
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

Review 6.  MicroRNAs in cancer.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

7.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.

Authors:  Thomas Thum; Carina Gross; Jan Fiedler; Thomas Fischer; Stephan Kissler; Markus Bussen; Paolo Galuppo; Steffen Just; Wolfgang Rottbauer; Stefan Frantz; Mirco Castoldi; Jürgen Soutschek; Victor Koteliansky; Andreas Rosenwald; M Albert Basson; Jonathan D Licht; John T R Pena; Sara H Rouhanifard; Martina U Muckenthaler; Thomas Tuschl; Gail R Martin; Johann Bauersachs; Stefan Engelhardt
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962

8.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.

Authors:  Huating Wang; Ramiro Garzon; Hao Sun; Katherine J Ladner; Ravi Singh; Jason Dahlman; Alfred Cheng; Brett M Hall; Stephen J Qualman; Dawn S Chandler; Carlo M Croce; Denis C Guttridge
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

9.  MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy.

Authors:  Qiang Wang; Youli Wang; Andrew W Minto; Jinhua Wang; Qun Shi; Xinmin Li; Richard J Quigg
Journal:  FASEB J       Date:  2008-08-20       Impact factor: 5.191

10.  Potent inhibition of microRNA in vivo without degradation.

Authors:  Scott Davis; Stephanie Propp; Susan M Freier; Laura E Jones; Martin J Serra; Garth Kinberger; Balkrishen Bhat; Eric E Swayze; C Frank Bennett; Christine Esau
Journal:  Nucleic Acids Res       Date:  2008-11-16       Impact factor: 16.971

View more
  128 in total

1.  Managing microvascular complications of diabetes with microRNAs.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 10.121

Review 2.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 3.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 4.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

5.  HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility.

Authors:  Allison Lesher Williams; Chad B Walton; Keith A MacCannell; Abigail Avelar; Ralph V Shohet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-12-21       Impact factor: 4.733

Review 6.  Early detection of diabetic kidney disease: Present limitations and future perspectives.

Authors:  Chih-Hung Lin; Yi-Cheng Chang; Lee-Ming Chuang
Journal:  World J Diabetes       Date:  2016-07-25

Review 7.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

8.  Dicer deficiency in proximal tubules exacerbates renal injury and tubulointerstitial fibrosis and upregulates Smad2/3.

Authors:  Zhengwei Ma; Qingqing Wei; Ming Zhang; Jian-Kang Chen; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-03

Review 9.  New insights into molecular mechanisms of diabetic kidney disease.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  Am J Kidney Dis       Date:  2014-02       Impact factor: 8.860

10.  Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy.

Authors:  Jamie Lin; Yuanyuan Shi; Hui Peng; Xiaojie Shen; Sandhya Thomas; Yanlin Wang; Luan D Truong; Stuart E Dryer; Zhaoyong Hu; Jing Xu
Journal:  J Pathol       Date:  2015-02-19       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.